ARDX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Ardelyx Inc

NASDAQ | ARDX

5.13

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 15, 2025)

$1.21B

Market Cap

-

P/E Ratio

-0.24

EPS

$6.78

52 Week High

$3.21

52 Week Low

HEALTHCARE

Sector

ARDX Chart

Recent Chart
Price Action

ARDX Technicals

Tags:

ARDX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $283M
Total Revenue $334M
Cost Of Revenue $51M
Costof Goods And Services Sold $51M
Operating Income -$28M
Selling General And Administrative $259M
Research And Development $52M
Operating Expenses $311M
Investment Income Net -
Net Interest Income -$20M
Interest Income -
Interest Expense $20M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.1M
Income Before Tax -$39M
Income Tax Expense $266K
Interest And Debt Expense -
Net Income From Continuing Operations -$39M
Comprehensive Income Net Of Tax -
Ebit -$19M
Ebitda -$17M
Net Income -$39M

Revenue & Profitability

Earnings Performance

ARDX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $436M
Total Current Assets $356M
Cash And Cash Equivalents At Carrying Value $65M
Cash And Short Term Investments $65M
Inventory $21M
Current Net Receivables $58M
Total Non Current Assets $79M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $185M
Other Current Assets $27M
Other Non Current Assets -
Total Liabilities $262M
Total Current Liabilities $78M
Current Accounts Payable $16M
Deferred Revenue -
Current Debt -
Short Term Debt $1.6M
Total Non Current Liabilities $185M
Capital Lease Obligations $2.6M
Long Term Debt $151M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $153M
Other Current Liabilities $50M
Other Non Current Liabilities -
Total Shareholder Equity $173M
Treasury Stock -
Retained Earnings -$885M
Common Stock $24K
Common Stock Shares Outstanding $235M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$45M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.1M
Capital Expenditures $1M
Change In Receivables -
Change In Inventory -$42M
Profit Loss -
Cashflow From Investment -$18M
Cashflow From Financing $107M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $8.1M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$39M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $283M
Total Revenue $334M
Cost Of Revenue $51M
Costof Goods And Services Sold $51M
Operating Income -$28M
Selling General And Administrative $259M
Research And Development $52M
Operating Expenses $311M
Investment Income Net -
Net Interest Income -$20M
Interest Income -
Interest Expense $20M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.1M
Income Before Tax -$39M
Income Tax Expense $266K
Interest And Debt Expense -
Net Income From Continuing Operations -$39M
Comprehensive Income Net Of Tax -
Ebit -$19M
Ebitda -$17M
Net Income -$39M

ARDX News

ARDX Profile

Ardelyx Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Ardelyx Inc. is a biopharmaceutical company located in Fremont, California, specializing in the development of transformative therapies for kidney and cardiorenal diseases, which represent substantial unmet medical needs. The company leverages its expertise in renal pharmacology to drive clinical development and commercial strategies aimed at improving patient outcomes. With a promising pipeline of innovative treatments and strategic collaborations, Ardelyx is poised to make significant advancements in therapeutic options that enhance the quality of life for patients suffering from complex renal disorders.

GNPX
+232.67%
$0.84
YYAI
-10.40%
$0.13
VHAI
-20.00%
$0.00
BURU
-17.95%
$0.33
NVDA
-0.11%
$179.83
CGBS
-39.47%
$0.03
TOVX
+92.08%
$0.84
COOT
+173.57%
$2.64
PLUG
-4.93%
$3.85
BITF
+9.84%
$6.47
DFLI
+28.75%
$1.97
NVTS
+20.60%
$15.16
CAN
+8.88%
$1.96
RGTI
+0.39%
$56.34
OMER
+154.14%
$10.42
TLRY
+5.00%
$1.68
DNN
-0.78%
$3.16
LAES
-2.09%
$7.49
AMD
+9.40%
$238.60
RXRX
+6.50%
$5.89
RR
-8.46%
$6.16
INTC
+4.26%
$37.15
ACHR
+0.07%
$13.03
BYND
-12.41%
$0.68
F
+0.94%
$11.76
QBTS
+3.99%
$44.78
QS
+5.74%
$17.85
YDKG
-86.28%
$0.19
TSLA
+1.37%
$435.15
IONZ
+12.06%
$2.88
BAC
+4.37%
$52.28
AXDX
-61.36%
$0.03
BBD
+1.58%
$3.20
ETHD
+6.47%
$3.78
NOK
+3.19%
$5.64
CIFR
+0.67%
$21.03
ADAP
+15.06%
$0.18
PFAI
+139.26%
$4.57
RIG
+5.44%
$3.29
SOFI
+0.57%
$28.03
SMR
+16.71%
$53.44
UUUU
-4.72%
$24.99
MARA
+2.69%
$22.84
BTBT
-1.69%
$4.05
FHN
-9.49%
$20.83
HIMS
+16.17%
$62.76
BTG
+5.99%
$5.66
QSI
+22.32%
$2.63
QUBT
-2.52%
$21.23
APLD
+7.76%
$37.76
CRML
-24.19%
$22.72
AAL
+2.54%
$12.50
SOUN
+2.32%
$21.34
NAK
-4.34%
$2.64
JOBY
-2.81%
$17.60
ONDS
-8.64%
$9.51
PFE
-0.53%
$24.39
IREN
-2.27%
$67.98
DVLT
-4.10%
$2.10
VERI
+53.66%
$8.39
SLNH
+53.76%
$4.29
WULF
+0.06%
$15.47
AMZN
-0.37%
$215.57
GDXD
-12.00%
$0.66
CLSK
+5.55%
$23.20
GPUS
-4.97%
$0.38
TMQ
-20.18%
$8.46
ATCH
+0.99%
$0.40
ABAT
-21.00%
$8.94
UAMY
-21.23%
$13.76
SEED
+51.91%
$2.18
RGTZ
-1.13%
$8.69
RMBL
+60.50%
$3.21
NIO
+0.29%
$6.82
SNAP
-0.12%
$7.91
WWR
-29.02%
$2.47
BMNR
+1.19%
$53.55
ADD
-25.47%
$0.05
VALE
+1.82%
$11.17
GRAB
+0.16%
$5.92
PLTR
-0.06%
$179.62
RF
-1.66%
$24.74
SANA
+33.03%
$5.92
SRM
+53.27%
$10.30
CLF
-0.07%
$13.95
ASST
-3.71%
$0.95
T
-0.22%
$26.07
NUAI
+9.12%
$3.35
NEHC
+9.12%
$3.35
NAKA
+1.29%
$0.79
OKLO
-1.48%
$171.56
KDLY
+1.29%
$0.79
AREC
-26.43%
$5.01
AAPL
+0.63%
$249.34
USAR
-10.29%
$33.68
HI
+18.19%
$31.31
EOSE
+7.65%
$18.28
CGC
+6.26%
$1.44
IONQ
-6.62%
$72.41
RIVN
+2.55%
$13.45
GNPX
+232.67%
$0.84
YYAI
-10.40%
$0.13
VHAI
-20.00%
$0.00
BURU
-17.95%
$0.33
NVDA
-0.11%
$179.83
CGBS
-39.47%
$0.03
TOVX
+92.08%
$0.84
COOT
+173.57%
$2.64
PLUG
-4.93%
$3.85
BITF
+9.84%
$6.47
DFLI
+28.75%
$1.97
NVTS
+20.60%
$15.16
CAN
+8.88%
$1.96
RGTI
+0.39%
$56.34
OMER
+154.14%
$10.42
TLRY
+5.00%
$1.68
DNN
-0.78%
$3.16
LAES
-2.09%
$7.49
AMD
+9.40%
$238.60
RXRX
+6.50%
$5.89
RR
-8.46%
$6.16
INTC
+4.26%
$37.15
ACHR
+0.07%
$13.03
BYND
-12.41%
$0.68
F
+0.94%
$11.76
QBTS
+3.99%
$44.78
QS
+5.74%
$17.85
YDKG
-86.28%
$0.19
TSLA
+1.37%
$435.15
IONZ
+12.06%
$2.88
BAC
+4.37%
$52.28
AXDX
-61.36%
$0.03
BBD
+1.58%
$3.20
ETHD
+6.47%
$3.78
NOK
+3.19%
$5.64
CIFR
+0.67%
$21.03
ADAP
+15.06%
$0.18
PFAI
+139.26%
$4.57
RIG
+5.44%
$3.29
SOFI
+0.57%
$28.03
SMR
+16.71%
$53.44
UUUU
-4.72%
$24.99
MARA
+2.69%
$22.84
BTBT
-1.69%
$4.05
FHN
-9.49%
$20.83
HIMS
+16.17%
$62.76
BTG
+5.99%
$5.66
QSI
+22.32%
$2.63
QUBT
-2.52%
$21.23
APLD
+7.76%
$37.76
CRML
-24.19%
$22.72
AAL
+2.54%
$12.50
SOUN
+2.32%
$21.34
NAK
-4.34%
$2.64
JOBY
-2.81%
$17.60
ONDS
-8.64%
$9.51
PFE
-0.53%
$24.39
IREN
-2.27%
$67.98
DVLT
-4.10%
$2.10
VERI
+53.66%
$8.39
SLNH
+53.76%
$4.29
WULF
+0.06%
$15.47
AMZN
-0.37%
$215.57
GDXD
-12.00%
$0.66
CLSK
+5.55%
$23.20
GPUS
-4.97%
$0.38
TMQ
-20.18%
$8.46
ATCH
+0.99%
$0.40
ABAT
-21.00%
$8.94
UAMY
-21.23%
$13.76
SEED
+51.91%
$2.18
RGTZ
-1.13%
$8.69
RMBL
+60.50%
$3.21
NIO
+0.29%
$6.82
SNAP
-0.12%
$7.91
WWR
-29.02%
$2.47
BMNR
+1.19%
$53.55
ADD
-25.47%
$0.05
VALE
+1.82%
$11.17
GRAB
+0.16%
$5.92
PLTR
-0.06%
$179.62
RF
-1.66%
$24.74
SANA
+33.03%
$5.92
SRM
+53.27%
$10.30
CLF
-0.07%
$13.95
ASST
-3.71%
$0.95
T
-0.22%
$26.07
NUAI
+9.12%
$3.35
NEHC
+9.12%
$3.35
NAKA
+1.29%
$0.79
OKLO
-1.48%
$171.56
KDLY
+1.29%
$0.79
AREC
-26.43%
$5.01
AAPL
+0.63%
$249.34
USAR
-10.29%
$33.68
HI
+18.19%
$31.31
EOSE
+7.65%
$18.28
CGC
+6.26%
$1.44
IONQ
-6.62%
$72.41
RIVN
+2.55%
$13.45
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.